ArticleClinicoEconomics and outcomes research : CEOR2021

Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.

Mary Slavcev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.